Biocytogen-B (02315) has completed its A-share issuance.

Biocytophen-B (02315) announced that the company has completed the A-share issuance. The company's A-share will be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board and will begin trading on December 10, 2025. The board of directors further announced that Dr. Zhang Haichao (Dr. Zhang) has resigned as an executive director of the company due to internal work adjustments, effective December 10, 2025. The board of directors also announced that in accordance with the Company Law, the company's articles of association, and the results of the employee representative congress held on December 5, 2025, Ms. Li Yan was elected as the employee representative director (employee director) of the second board of directors. Ms. Li's term will start from the date of the company's A-share listing on the Sci-Tech Innovation Board and will end on the expiration date of the second board of directors' term.